Term
|
Definition
Alkylating Agents (Nitrogen Mustard)
PO, IV
Lymphoma, leukemia, solid tumors
Hemorrhagic cystitis, CNS Toxicity |
|
|
Term
|
Definition
Alkylating Agent (Nitrogen Mustard)
IV
Lymphoma, leukemia, solid tumors
Hemorrhagic cystitis, cardiotoxic |
|
|
Term
|
Definition
Alkylating Agents (Nitrogen Mustard)
PO
Leukemia, lymphoma |
|
|
Term
|
Definition
Alkylating Agents (Nitrogen Mustard)
IV
Leukemia, lymphoma |
|
|
Term
|
Definition
Alkylating Agents (Nitrogen Mustard)
IV
Leukemia, lymphoma |
|
|
Term
|
Definition
Alkylating Agents (Alkyl Sulfonates)
IV, PO
Leukemia, lymphoma
Hepatotoxicity |
|
|
Term
|
Definition
Alkylating Agents (Triazene & Hydrazine)
IV
Leukemia, lymphoma |
|
|
Term
|
Definition
Alkylating Agents (Triazene & Hydrazine)
PO
Leukemia, lymphoma |
|
|
Term
|
Definition
Alkylating Agents (Platinum Coordination Complex)
IV
Solid tumors
Nephrotixicity, Ototoxicity, Peripheral Neuropathy |
|
|
Term
|
Definition
Alkylating Agents (Platinum Coordination Complex)
IV
Solid Tumors |
|
|
Term
|
Definition
Alkylating Agents (Platinum Coordination Complex)
IV
Solid Tumors
Peripheral Neuropathy |
|
|
Term
|
Definition
Antimetabolite (Folic Acid Analog)
DHFR Inhibitor
IV
Solid Tumors
Nephrotoxicity (rescued by leucovorin) |
|
|
Term
|
Definition
Antimetabolite (Folic Acid Analog)
IV
Solid Tumors
Nephrotoxicity |
|
|
Term
|
Definition
Antimetabolite (Pyrimidine Analog)
Blocks thymidylate synthesis
IV
Solid tumor
Leucovorin enhances activity
Hand-foot syndrome |
|
|
Term
|
Definition
Antimetabolite (Pyrimidine Analog)
Blocks thymidylate synthesis
PO (5-FU prodrug)
Solid tumor
Leucovorin enhances activity
Hand-foot syndrome |
|
|
Term
|
Definition
Antimetabolite (Pyrimidine Analog)
IV
Leukemia
CNS toxicity |
|
|
Term
|
Definition
Antimetabolite (Pyrimidine Analog)
IV
Solid tumor
Hepatotoxicity |
|
|
Term
|
Definition
Antimetabolite (Pyrimidine Analog)
IV, SC
Leukemia, lymphoma |
|
|
Term
|
Definition
Antimetabolite (Pyrimidine Analog)
IV
Leukemia, lymphoma |
|
|
Term
|
Definition
Antimetabolite (Purine Analog)
PO
Leukemia, lymphoma
Hyperuricemia (alleviated by allopurinol, requires 75% dose reduction) |
|
|
Term
|
Definition
Antimetabolite (Purine Analog)
IV, PO
Leukemia, lymphoma
Autoimmune Effects (hemolytic anemia) |
|
|
Term
|
Definition
Antimetabolite (Purine Analog)
IV
Leukemia, Lymphoma
CNS toxicity |
|
|
Term
|
Definition
Antimetabolite (Purine Analog)
IV
Leukemia, lymphoma
Capillary leaks (SIRS) |
|
|
Term
|
Definition
Antimetabolite (Purine Analog)
IV
Leukemia, Lymphoma
Neurotoxicity |
|
|
Term
|
Definition
Antimetabolite (Purine Analog)
IV
Leukemia, Lymphoma |
|
|
Term
|
Definition
Antimetabolite (Purine Analog)
Inhibits ribonucleotide reductase
PO
Cutaneous vasculitic toxicity, secondary malignancy |
|
|
Term
|
Definition
Topoisomerase I Inhibitor
IV
Solid Tumors
Rapidly hydrolyzed in water |
|
|
Term
|
Definition
Topoisomerase I Inhibitor
IV
Solid Tumor
SN-38 is active form
Diarrhea
Given in polysorbate 80 (hypersensitivity reactions) |
|
|
Term
|
Definition
Topoisomerase II Inhibitor (Anthracycline)
IV
Solid Tumor, lymphoma, leukemia
Cardiotoxicity (can give dexrazoxane), Vesicant |
|
|
Term
|
Definition
Topoisomerase II Inhibitor (Anthracycline)
IV
Solid Tumor
Less cardiotoxicitity but hand-foot syndrome |
|
|
Term
|
Definition
Topoisomerase II Inhibitor (Anthracycline)
IV
Leukemia, Lymphoma
Cardiotoxicity (can give dexrazoxane), Vesicant
Red color urine |
|
|
Term
|
Definition
Topoisomerase II Inhibitor (Anthracycline)
IV
Leukemia, lymphoma
Cardiotoxicity (can give dexrazoxane), Vesicant |
|
|
Term
|
Definition
Topoisomerase II Inhibitor (Anthracycline)
IV
Solid Tumor
Cardiotoxicity (can give dexrazoxane), Vesicant |
|
|
Term
|
Definition
Topoisomerase II Inhibitor (Anthracycline)
IV
Solid Tumor
Less cardiotoxicity |
|
|
Term
|
Definition
Topoisomerase II Inhibitor (Epipdophyllotoxins)
IV (double dose for PO)
Solid tumor
Given in polysorbate 80 (Hypersensitivity) |
|
|
Term
|
Definition
Topoisomerase II Inhibitor (Epipdophyllotoxins)
IV
Leukemia, lymphoma, solid tumor
Given in Cremophor LE (more hypersensitivity) |
|
|
Term
|
Definition
Antimitotic (Vinca Alkaloid)
Blocks polymerization
IV
Leukemia, lymphoma, solid tumors
Neurotoxicity and vesicant |
|
|
Term
|
Definition
Antimitotic (Vinca Alkaloid)
Blocks polymerization
IV
Leukemia, lymphoma, solid tumors
Vesicant |
|
|
Term
|
Definition
Antimitotic (Vinca Alkaloid)
Blocks polymerization
IV
Leukemia, lymphoma, solid tumors
Vesicant |
|
|
Term
|
Definition
Antimitotic (Vinca Alkaloid)
Blocks polymerization
IV
Solid Tumors
Vesicant |
|
|
Term
|
Definition
Antimitotic (Taxane)
Promotes polymerization
IV
Solid tumors
Cremophor EL (Hypersensitivity) |
|
|
Term
|
Definition
Antimitotic (Taxane)
Promotes polymerization
IV
Solid tumors
No hypersensitivity |
|
|
Term
|
Definition
Antimitotic (Taxane)
Promotes polymerization
IV
Solid tumors
Polysorbate 80 (Hypersensitivity) |
|
|
Term
|
Definition
Antimitotic (Taxane)
Promotes polymerization
IV
Solid tumors
Cremophor EL (Hypersensitivity) |
|
|
Term
|
Definition
Antimitotic (Taxane)
Promotes polymerization
IV
Solid tumors
Cremophor El (Hypersensitivity) |
|
|
Term
|
Definition
Antimitotic
Blocks polymerization
IV
Solid tumors
Peripheral neuropathy |
|
|
Term
|
Definition
Antimitotic
Blocks polymerization
PO
Solid tumor
Cardiotoxicity, estrogen effect, fluid retention |
|
|
Term
|
Definition
Differentiating Agent
Degrades PML-RAR-a
PO
Leukemia
APL differentiation syndrome |
|
|
Term
|
Definition
Differentiating Agent
Degrades PML-RAR-a
IV
Leukemia
APL Differntiation syndrome, cardiotoxicity |
|
|
Term
|
Definition
Anti-Hormonal (SERM)
PO
ER positive breast cancer
Increased risk for uterine cancer, hot flashes, decrease bone mineral density |
|
|
Term
|
Definition
Anti-Hormonal (SERM)
PO
ER positive breast cancer
Hot flashes |
|
|
Term
|
Definition
Anti-Hormonal (SERM)
PO
ER positive breast cancer
Hot flashes, increased risk for stroke |
|
|
Term
|
Definition
Anti-Hormonal (SERD)
IM
ER positive breast cancer
Hot flashes |
|
|
Term
|
Definition
Anti-Hormonal (LHRH)
SC
Breast, prostate
Decrease bone mineral density, hot flashes |
|
|
Term
|
Definition
Anti-Hormonal (LHRH)
Synthetic progesterone
PO
ER positive breast cancer
Hot flashes |
|
|
Term
|
Definition
Anti-Hormonal (Aromatase Inhibitor)
PO
ER positive breast cancer
Hot flashes, decreased bone mineral density |
|
|
Term
|
Definition
Anti-Hormonal (Aromatase Inhibitor)
PO
ER positive breast cancer
Decreased bone mineral density, hot flashes |
|
|
Term
|
Definition
Anti-Hormonal (Aromatase Inhibitor)
PO
ER positive breast cancer
Decreased bone mineral density, hot flashes |
|
|
Term
|
Definition
Anti-Hormonal (Androgen Deprivation Therapy)
SC
Prostate Cancer
Decreased bone mineral density, tumor flare, hot flash |
|
|
Term
|
Definition
Anti-Hormonal (Androgen Deprivation Therapy)
Prostate
Hypersensitivity reactions |
|
|
Term
|
Definition
Anti-Hormonal (Androgen Deprivation Therapy)
LHRH Antagonist, no tumor flare
SC
Hot flashes |
|
|
Term
|
Definition
Anti-Hormonal (Androgen Deprivation Therapy)
PO
Prostate
Hepatotoxicity |
|
|
Term
|
Definition
Anti-Hormonal (Androgen Deprivation Therapy)
PO
Prostate |
|
|
Term
|
Definition
Anti-Hormonal (Androgen Deprivation Therapy)
PO
Prostate
Night blindness |
|
|
Term
|
Definition
Inhibits NFkB by degrading IkB
IV or SC
Myeloma, lymphoma
Peripheral neuropathy |
|
|
Term
|
Definition
MOA unsure
PO
Myeloma
TERATOGEN, DVT, neurotoxicity |
|
|
Term
|
Definition
MOA unknown
PO
Myeloma
Less toxic than thalidomide but same toxicities |
|
|
Term
|
Definition
Cleaves L-asparagine and inhibits protein synthesis
IV, IM
Leukemia
Hypersensitivity, hepatotoxicity, clotting abnormalities, increased TGs, pancreatitis |
|
|
Term
|
Definition
Breaks DNA strands
IV, IM, or SC
Solid tumor, lymphoma
Max 400 units in lifetime due to pulmonary fibrosis
Hypersensitivity |
|
|
Term
|
Definition
BCR-ABL Kinase Inhibitor
PO
Ph+ CML
Hepatotoxicity, hemorrhage |
|
|
Term
|
Definition
BCR-ABL Kinase Inhibitor
PO
Ph+ CML
Use when resistant or intolerant to imatinib
Cardiotoxicity, less hemorrhage |
|
|
Term
|
Definition
BCR-ABL Kinase Inhibitor
Ph+ CML
PO
Use when resistant or intolerant to imatinib |
|
|
Term
|
Definition
EGFR Inhibitor
PO
Lung Cancer
Rash |
|
|
Term
|
Definition
EGFR Inhibitor
PO
Lung Cancer
Rash |
|
|
Term
|
Definition
EGFR Inhibitor
PO
Breast Cancer (HER2/Neu)
Rash |
|
|
Term
|
Definition
BRAFv600E Inhibitor
PO
BRAF positive melanoma
Hypersensitivity, cardiotoxicity, cutaneous squamous cell carcinoma |
|
|
Term
|
Definition
EML4-ALK Inhibitor
PO
Vision impairment, cardiotoxicity |
|
|
Term
|
Definition
Anti-CD20, ADCC and CDC
IV
Leukemia, lymphoma
Infusion reactions |
|
|
Term
|
Definition
IV
Leukemia
Infusion reactions |
|
|
Term
|
Definition
Anti-CD52, ADCC and CDC
IV
Leukemia
Infusion reactions and Myelosuppresion |
|
|
Term
|
Definition
Chimeric antibody for CD30
IV
Lymphoma
Neurotoxicity, infusion reactions |
|
|
Term
|
Definition
Humanized mAb against VEGF
IV
Hemorrhage, poor wound healing |
|
|
Term
|
Definition
Chimeric mAb against EGFR
IV
Infusion reactions |
|
|
Term
|
Definition
Human mAb against EGFR
IV
Pulmonary toxicity |
|
|
Term
|
Definition
Humanized mAb against HER2/neu
IV
Breast cancer
Cardiotoxicity, do not give with cyclophosphamide, doxorubicin |
|
|
